CN1382688A - Chromone compounds with antineoplastic activity and its open-loop products and preparing process - Google Patents
Chromone compounds with antineoplastic activity and its open-loop products and preparing process Download PDFInfo
- Publication number
- CN1382688A CN1382688A CN 02112875 CN02112875A CN1382688A CN 1382688 A CN1382688 A CN 1382688A CN 02112875 CN02112875 CN 02112875 CN 02112875 A CN02112875 A CN 02112875A CN 1382688 A CN1382688 A CN 1382688A
- Authority
- CN
- China
- Prior art keywords
- general formula
- compound
- replacement
- open
- benzoxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A novel chromone compound with antineoplastic activity, its open-loop product, and their preparing process are disclosed.
Description
Technical field
The present invention relates to new chromone compounds and chromone open-loop products, with and preparation method thereof with application in the medicine of preparation treatment tumour.
Background technology
People such as K.R.S.Reddy are at India chemistry meeting magazine (J.Indian Chem.Soc., 1986,7-methoxyl group-2-(2-benzimidazolyl-) chromonic compound and synthetic method thereof with anti-microbial activity are disclosed pp600-602), it is a starting raw material with 7-methoxyl group chromone-2-methyl-formiate, in polyphosphoric acid, directly obtain target product with O-Phenylene Diamine in 170 ℃ of reactions, perhaps make amide intermediate 100 ℃ of reactions, in polyphosphoric acid, obtain the target product then in 170 ℃ of cyclizations with 7-methoxyl group chromone-2-methyl-formiate and O-Phenylene Diamine.
Summary of the invention
The technical problem to be solved in the present invention provides new chromone compounds with anti-tumor activity and chromone open-loop products, and its corresponding preparation method is provided simultaneously.
The technical problem to be solved in the present invention comprises that with the chromone carboxylic acid be starting raw material, preparation acyl chlorides, amide intermediate, and the method for cyclization has prepared a series of new chromone compounds and chromone open-loop products then, and these compounds have better antitumor activity.
Technical scheme of the present invention is:
Following general formula (I) compound and open-loop products general formula (II) compound thereof
R wherein
1Expression carboxyl, benzoglyoxaline, benzoxazole, benzothiazole, the benzoglyoxaline of replacement, the benzoxazole of replacement or the benzothiazole of replacement; R
2Expression benzoglyoxaline, benzoxazole, benzothiazole, the benzoglyoxaline of replacement, the benzoxazole of replacement, the benzothiazole or the halogen of replacement; R
3Expression hydroxyl, C
1～10Alkoxyl group, nitro, amino or halogen; R
4Expression H, C
1～10Alkyl, arylalkyl, C
1～10Alkyloyl or aromatic yl silane terephthalamide yl.And, do not comprise R in the general formula (I)
1=2-benzoglyoxaline, R
2=H, R
3=OCH
3Compound.
According to above-mentioned general formula (I) compound and open-loop products general formula (II) compound thereof, it is characterized in that: R
2Or R
3The halogen of representative is F, Cl, Br or I.
According to aforementioned formula (I) compound and open-loop products general formula (II) compound thereof, it is characterized in that: R
1Or R
2Benzoglyoxaline, the benzoxazole of replacement or the benzothiazole of replacement of the replacement of representative, being meant has NO on the phenyl ring
2, single substituting group of F, Cl, Br or I or disubstituted.
According to aforementioned formula (I) compound and open-loop products general formula (II) compound thereof, it is characterized in that: R
4Aryl in aryl, the arylalkyl of representative, the aromatic yl silane terephthalamide yl can be halogen, C
1～10Alkyl, C
1～10Alkoxyl group, the nitro benzene, biphenyl or the naphthalene that replace; R
4Alkyl in the arylalkyl of representative can be C
1～10Alkyl; Alkyloyl in the aromatic yl silane terephthalamide yl can be C
1～10Alkyloyl.
Aforementioned any one application of compound in the medicine of preparation treatment tumour.
The preparation method of above-mentioned general formula (I) compound and open-loop products general formula (II) compound thereof is characterized in that this method may further comprise the steps:
A. the chromone carboxylic acid that following general formula (A) expression replaces, with general formula (A) and phosphorus pentachloride in toluene
The corresponding acyl chlorides of prepared in reaction;
General formula (A)
R in the general formula (A)
1Be carboxyl, methoxycarbonyl base or ethoxycarbonyl; R
2Be carboxyl or halogen; R
3Expression C
1～10Alkoxyl group, nitro or halogen;
B. with gained acyl chlorides and O-Phenylene Diamine, Ortho-Aminophenol, o-amino thiophenol, the O-Phenylene Diamine of replacement, the Ortho-Aminophenol of replacement or the o-amino thiophenol prepared in reaction corresponding amide intermediate of replacement; The o-amino thiophenol of the O-Phenylene Diamine of described replacement, the Ortho-Aminophenol of replacement or replacement is meant on the phenyl ring of O-Phenylene Diamine, Ortho-Aminophenol or o-amino thiophenol NO
2, single substituting group of F, Cl, Br or I or disubstituted.
C. with above-mentioned gained amide intermediate in polyphosphoric acid in 70～160 ℃ of cyclizations, general formula (I) compound; Perhaps with above-mentioned gained amide intermediate in polyphosphoric acid in 140～190 ℃ of cyclizations, R
4Be general formula (II) compound of H, hydrocarbonylation or acidylate get R
4The general formula of hydrocarbonylation or acidylate (II) compound; Wherein, amino general formula (I) that replaces and general formula (II) compound obtain corresponding nitro-compound reduction; And general formula (I) that hydroxyl replaces and general formula (II) compound are that the compound demethylation of corresponding methoxyl group replacement is obtained.
Preparation method according to described general formula (I) and open-loop products general formula (II) compound thereof is characterized in that: c. will through a, b step gained acid amides in polyphosphoric acid in 100～140 ℃ of cyclizations, general formula (I) compound; Perhaps with above-mentioned gained acid amides in polyphosphoric acid in 160～180 ℃ of cyclizations, R
4Be general formula (II) compound of H, hydrocarbonylation or acidylate get R
4General formula (II) compound for hydrocarbonylation or acidylate.
The preparation method of the general formula that the present invention relates to (I) chromone compounds can be represented by synthetic synoptic diagram 1～3:
A. with the chromone-2-formic acid (seeing synthetic synoptic diagram 1) that replaces or chromone-6-formic acid (seeing synthetic synoptic diagram 2) that replaces or the chromone-2 that replaces, 6-dioctyl phthalate (seeing synthetic synoptic diagram 3) and the corresponding acyl chlorides of phosphorus pentachloride prepared in reaction in toluene;
B. the o-amino thiophenol prepared in reaction amide intermediate of the Ortho-Aminophenol of the O-Phenylene Diamine of acyl chlorides and O-Phenylene Diamine, Ortho-Aminophenol, o-amino thiophenol, replacement, replacement or replacement;
C. with amide intermediate in polyphosphoric acid (PPA) in 70～160 ℃ of cyclizations;
General formula (I) compound that amino wherein replaces obtains corresponding nitro-compound reduction; And general formula (I) compound that hydroxyl replaces is the compound demethylation that corresponding methoxyl group is replaced and obtaining.Synthetic synoptic diagram 1
Synthetic synoptic diagram 2
Synthetic synoptic diagram 3
In the above-mentioned synthetic synoptic diagram 1～3, R
1Be methoxycarbonyl base, ethoxycarbonyl; R
2Be halogen; R
3Expression C
1～10Alkoxyl group, nitro, halogen; R represents that H or NO are arranged on the phenyl ring
2, single substituting group of F, Cl, Br or I or disubstituted; X is NH, O, S.
General formula of the present invention (II) compound is the open-loop products of general formula (I) compound, and its preparation method can be represented with synthetic synoptic diagram 4～6:
A. with the chromone-2-formic acid (seeing synthetic synoptic diagram 4) that replaces or chromone-6-formic acid (seeing synthetic synoptic diagram 5) that replaces or the chromone-2 that replaces, 6-dioctyl phthalate (seeing synthetic synoptic diagram 6) and the corresponding acyl chlorides of phosphorus pentachloride prepared in reaction in toluene;
B. the o-amino thiophenol of the Ortho-Aminophenol of the O-Phenylene Diamine of acyl chlorides and O-Phenylene Diamine, Ortho-Aminophenol, o-amino thiophenol, replacement, replacement or replacement prepared in reaction amide intermediate in methylene dichloride;
C. with amide intermediate in polyphosphoric acid in 140～190 ℃ of cyclizations.
Synthetic synoptic diagram 4
Synthetic synoptic diagram 5
Synthetic synoptic diagram 6
In the above-mentioned synthetic synoptic diagram 4～6, R
1Be methoxycarbonyl base, ethoxycarbonyl; R
2Be halogen; R
3Expression C
1～10Alkoxyl group, nitro, halogen; R
4Be hydrogen; R represents that H or NO are arranged on the phenyl ring
2, F, Cl, Br or the single of I replace or two replacement; X is NH, O, S.
R
4Expression C
1～10The The compounds of this invention of alkyl, arylalkyl is with above-mentioned R
4For the product of hydrogen is a raw material, make R according to the method hydrocarbonylation of chemical field routine
4This compound of expression acyl group also is with above-mentioned R
4For the product of hydrogen is a raw material, make according to the method acidylate of chemical field routine.
Wherein, amino general formula (II) compound that replaces obtains corresponding nitro-compound reduction; And general formula (II) compound that hydroxyl replaces is the compound demethylation that corresponding methoxyl group is replaced and obtaining.
The ratio of open-loop products and open-loop products does not change with the variation of temperature of reaction and time.For example, with 7-methoxyl group-2-chromone formic acid is that starting raw material makes its acyl chlorides, behind its corresponding amide intermediate of Ortho-Aminophenol prepared in reaction, if amide intermediate in polyphosphoric acid in 130 ℃ the reaction 1.5 hours, the ratio of open-loop products and open-loop products is not 95/5; If in 130 ℃ of reactions 3 hours, the ratio of open-loop products and open-loop products was not 86/14 to amide intermediate in polyphosphoric acid; If in 150 ℃ of reactions 4.5 hours, the ratio of open-loop products and open-loop products was not 61/39 to amide intermediate in polyphosphoric acid.
At present, the screening of antineoplastic compound is that cytotoxic activity with compound embodies routinely.
Experimental data shows: The compounds of this invention is that (A2780) and human liver cancer cell 7402 are that (Bel7402) has stronger cytotoxicity to human oral epidermoid carcinoma cell (KB), Proliferation of Human Ovarian Cell 2780.
The following examples can make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
Embodiment
The manufacturer of agents useful for same and specification among the following embodiment:
Reagent name manufacturer rank specification
The chemical pure 500ml of polyphosphoric acid Shanghai amalgamation factory
Chemical pure 100g is sold at chemical reagent station, O-Phenylene Diamine Shanghai
O-aminophenol Shanghai chemical reagent purchasing and supply station is sold chemical pure 100g
The analytical pure 500ml of methylene dichloride Shanghai chemical reagent company limited
The analytical pure 500ml of triethylamine Shanghai Ling Feng chemical reagent company limited
The new chemical reagent of the phosphorus pentachloride booth chemical pure 500g of factory
The chemical pure 100g of ethyl p-hydroxybenzoate China Medicine (Group) Shanghai Chemical Reagent Co.,
The analytical pure 100g of Resorcinol Shanghai white crane pesticide chemical factory
Embodiment 1
The preparation of raw material 7-methoxyl group-2-chromone formic acid
1) preparation 2, the 4-resacetophenone
Anhydrous ZnCl with fusion
2(80 gram) is dissolved in the Glacial acetic acid (170ml) fully; add then Resorcinol (62.5 the gram, 0.57mol), nitrogen protection; refluxed about 3.5 hours; cooling is stirred and is slowly poured into down in about 400 gram trash ices, separates out yellow solid; re-crystallizing in ethyl acetate; get faint yellow solid 60 grams, yield 69.5%, mp143-144 ℃ (literature value 142-144 ℃).
2) preparation 7-hydroxyl chromone-2-ethyl formate
In the 1000ml three-necked bottle of being furnished with mechanical stirring, prolong and drying tube, add dehydrated alcohol 350ml, and sodium Metal 99.5 (20.7 grams, 0.9mol).After question response is cooled to below 10 ℃ fully, under agitation drips and be dissolved in alcoholic acid 2, the 4-resacetophenone (34.2 grams, 0.225mol) and oxalic acid diethyl ester (temperature is in 10 ℃ in the control for 90ml, mixed solution 0.66mol).Finish, room temperature was placed 1～2 hour, refluxed about 4 hours, and cooling adds about 500ml anhydrous diethyl ether, and placement is spent the night.Suction filtration is put into 500ml with the gained solid and is burnt the bosom, puts refrigerator and cooled and but adds trash ice in the back, and dense HCl transfers about pH3 with refrigerative, uses ethyl acetate extraction, anhydrous Na
2SO
4Drying, the recovery ethyl acetate, the ethanolic soln with the saturated hydrogenchloride of 100ml refluxed 1 hour then, and cooling is filtered, and gets faint yellow solid 25.6 grams, yield 48.2%, mp219-221 ℃ (literature value 219-221 ℃).
3) preparation 7-methoxyl group chromone-2-ethyl formate
In the reaction flask of being furnished with prolong, drying tube, add 7-hydroxyl chromone-2-ethyl formate (23.6 grams, 0.1mol), Anhydrous potassium carbonate (15.6 the gram, 0.11mol) and anhydrous propanone (130ml), about 10 minutes of stirring at room, add methyl iodide (6.8ml then, 0.11mol), about 2 hours of reflux.Filtered while hot is used the washing with acetone filter cake, reclaims acetone, gets gray solid 20 grams, yield 80%, mp189-192 ℃.
4) preparation 7-methoxyl group-2-chromone formic acid
7-methoxyl group chromone-2-ethyl formate (20 grams, 0.8mol), the mixing solutions (100ml) of the dense HCl of HOAc-(5: 1) is added in the 250ml reaction flask, is heated to backflow, and the solid dissolving has solid to separate out then, and reaction in about 1.5 hours finishes.Cooling adds the suitable quantity of water dilution, leaves standstill, and filters, and gets pale solid 15 grams, yield 84.5%, mp272-4 ℃ (272 ℃ of literature values).
Embodiment 2
The preparation of raw material 2-ethoxycarbonyl-6-chromone formic acid
1) preparation is to the acetoxy-benzoic acid ethyl ester
(72.5 grams, 0.41mol), (70ml's aceticanhydride 0.73mol), refluxed about 3 hours, and cooling concentrates, and adds suitable quantity of water then, Na to add ethyl p-hydroxybenzoate in the reaction flask of being furnished with drying tube and prolong
2CO
3The aqueous solution is transferred pH to 8, filters, and gets white solid 81.5 grams, yield 91%, mp50-52 ℃.
2) preparation 2-ethanoyl-4-hydroxy-benzoic acid
In the 1000ml three-necked bottle of being furnished with mechanical stirring, prolong, drying tube and device for absorbing tail gas, add acetoxy-benzoic acid ethyl ester (35 grams, 0.181mol), Repone K (21 gram), aluminum chloride (71 grams, 0.533mol), be heated to 155 ℃ (outer temperature), emit a large amount of hydrogenchloride, stop in the time of extremely can not stirring stirring, be incubated 1.5 hours, after the ice bath cooling, add 2N hydrochloric acid (664ml), ethanol (110ml), refluxed 1.5 hours. cooling, separate out yellow solid, filter, washing gets yellow solid.Be further purified and earlier this product be dissolved in Na
2CO
3In the aqueous solution, and then transfer to acid getting final product with hydrochloric acid.Get faint yellow solid 18.5 grams, yield 61.7%, mp.243-5 ℃ (242 ℃ of literature values).
3) preparation 2-ethoxycarbonyl-6-chromone formic acid
Press the method preparation of 7-hydroxyl chromone-2-ethyl formate, different is that last cyclization got final product with the tetrahydrofuran solution backflow of saturated hydrogenchloride in 1.5 hours.Get gray solid 17 grams, yield 31.1%, mp277-8 ℃.
1HNMR(δ，ppm，DMSO-d
6)：1.35(t，3H，CH
3)，4.40(q，2H，CH
2)，6.98(s，1H，3-H)，7.82(d，1H，J＝8.8Hz，8-H)，8.30(dd，1H，J＝2.1Hz，7-H)，8.54(d，1H，J＝2.1Hz，5-H)；IR(cm
-1)：3409，3073，2980，2934，2605，2500-3100，1742，1712，1695，1655，1620，1599，1265，1098，768，519。
Embodiment 3
Preparation 2,6-chromone dioctyl phthalate
Got by 2-ethoxycarbonyl-6-chromone formic acid hydrolysis, method is with the hydrolysis of 7-methoxyl group-2-chromone ethyl formate, mp 305-8 ℃.
1HNMR(δ，ppm，DMSO-d
6)：6.96(s，1H，3-H)，7.82(d，1H，8-H)，8.31(dd，1H，7-H)，8.55(d，1H，5-H)，13.2(br.)；IR(cm
-1)：3400，3104，2400-3300，1749，1697，1634，1603，1425，1279，1220，862，709。
Embodiment 4:
The preparation of 7-methoxyl group-2-(2-benzoxazole) chromone
7-methoxyl group chromone-2-formic acid (10 the gram, 0.045mol), phosphorus pentachloride (9.5 the gram, 0.045mol) and toluene (80ml) add in the reaction flask, be heated with stirring to 75-80 ℃ under the drying regime, do not emit to there being hydrogen chloride gas.Reclaim toluene, the gained solid is dissolved among an amount of anhydrous THF.(4.9 grams in THF solution 0.045mol), drip Et to drop to o-aminophenol under the ice bath cooling
3It is alkalescence that N keeps reaction solution, finishes about 24 hours of stirring at room.Filter, washing, drying, the THF recrystallization gets acid amides (3.2 gram), is yellow solid.This yellow solid (3.2 gram) and polyphosphoric acid (25ml) mixture are heated to 110 ℃ under nitrogen protection, are incubated 3.5 hours.Be cooled to 100 ℃, in the slow a large amount of trash ices of impouring, separate out gray solid under the vigorous stirring, filter washing, filter cake Na
2CO
3The aqueous solution is neutralized to pH8, filters, and drying, column chromatography is an elutriant with ethyl acetate/petroleum ether (v/v, 10/6), gets faint yellow solid 2 grams, yield 15%, mp201-4 ℃.IR:3082,2985,1646,1638,1612,1532;
1HNMR (δ, ppm, DMSO-d
6): 3.96 (S, 3H, OCH
3), 6.55-6.58 (d, 1H, 8-H), 6.89 (s, 1H, 3-H), 7.30-7.33 (t, 1H, 6-H), 7.49-7.60 (m, 2H, 5 ', 6 '-H), 7.86-7.99 (m, 1H, 7 '-H), 7.99-8.02 (d, 1H, 4 '-H), 8.26 (1H, d, 5-H); HREIMS (M): observed value 293.068904, C
17H
11NO
4, calculated value 293.068801;
Embodiment 5
2,6-two (2-benzoxazole)-4-oxygen-4H, the preparation of 1-chromene
Synthetic according to the preparation method of 6-methoxyl group-2-(2-benzoxazole) chromone, institute is not both, and the mole number of o-aminophenol is a chromone-2, two times of 6-dioctyl phthalate.Product is a pink solid, yield 19%, mp 303-4 ℃.IR (cm
-1): 3010,1650,1625,1530;
1HNMR (δ, ppm, DMSO-d6): 7.23 (s, 1H, 3-H), 7.39-7.46 (m, 2H, 6 ', 6 " H), (5 ' or 5 is " H) for t, 1H for 7.49-7.53,7.56-7.61 (t, 1H, 5 " or5 '-H), 7.80-7.82 (d, 2H; 7 ', 7 " H), 7.90-7.96 (t, 2H, 4 ', 4 " H), 8.01-8.04 (d, 1H, 8-H), 8.57-8.60 (dd; 1H, 7-H), 8.74 (S, 1H, 5-H); HREIMS (M): observed value 380.078859, C
23H
12N
2O
4, calculated value 380.079699; MS (EI): 380 (M
+).
Embodiment 6
The preparation of 6-(2-benzoglyoxaline)-2-chromone formic acid
(8 grams, 0.0305mol), (6.36 grams 0.0305mol) and toluene (75ml), are heated to 75-80 ℃ to phosphorus pentachloride to 2-ethoxycarbonyl chromone-6-formic acid under the anhydrous condition, till not having hydrogen chloride gas and emitting.Cold slightly, reclaim toluene, drain.Solid is dissolved among the anhydrous THF, and (3.3 grams in THF solution 0.0305mol), drip Et simultaneously to drop to O-Phenylene Diamine under the ice bath cooling
3It is alkalescence that N keeps reaction mixture, finishes about 24 hours of stirring at room.Concentrate, filter, washing, re-crystallizing in ethyl acetate gets acid amides (2.5 gram), is faint yellow solid, yield 25.3%.With the gained amide intermediate (2.5 grams, 0.0077mol) and PPA (20ml) be added in the reaction flask, reacted 3.5 hours in 140 ℃ under the nitrogen protection.After waiting to be chilled to 100 ℃, in the slow a large amount of trash ices of impouring, and vigorous stirring, separate out brown solid, filter, washing, drying, column chromatography is an elutriant with ethanol, gets brown solid (0.4 gram), yield 16.9%, mp293-5 ℃.IR (cm
-1): 3427,3000-2500,1650,1613,1568;
1HNMR (δ, ppm, DMSO-d
6): 6.9 (s, 1H, 3-H), 7.22-7.25 (q, 2H, 5 ', 6 '-H), 7.61-7.64 (q, 2H, 4 ', 7 '-H '), 7.89-7.92 (d, 1H, 8-H), 8.62-8.66 (dd, 1H, 7-H), 8.84 (d, 1H, 5-H); HREIMS (M): observed value 306.064541, C
17H
10N
2O
4, calculated value 306.064050;
Embodiment 7
2-(the preparation of 2-hydroxyl-4-anisoyl methyl formyl radical) benzoxazole
The preparation method is with 7-methoxyl group-2-(2-benzoxazole) chromone, and different is that interior warm at 180 ℃ during cyclization, product is a white, needle-shaped crystals, yield 21%, mp262-4 ℃.Ultimate analysis: observed value C 65.32, H 4.09, and N 4.36%, C
17H
13NO
5, calculated value C 65.59, H 4.18, and N 4.50%; HRESI-MS (M+1): observed value 312.0858, C
17H
13NO
5, calculated value 312.0866; EI (m/e) (M
+311,48%), 283 (32), 175 (37), 147 (100), 122 (10), 78 (14); IRcm
-13357 (ν
OH), 3010 (ν
Ar-H), 1694,1679,1610,1585,1498; NMR: δ
H3.01 (d, J=18Hz, 1H, COCHCO), 3.77 (d, J=18Hz, 1H, COCHCO), 3.43 (s, 3H, OCH
3), 6.06 (d, 1H, 3 ' H), 6.57 (dd, 1H, 5 '-H), 7.17-7.22 (m, 1H, 7-H), 6.89-6.92 (m, 1H, 5 or 6-H), 7.02-7.09 (m, 1H, 6 or 5-H), 7.32-7.37 (m, 1H, 4-H), 7.69 (d, 1H, 6 '-H), 10.69 (s, 1H, OH); δ
C165.2 (CO
*2), 159.1,157.5,140.3,128.6,128.1,124.3,124.1,117.3,115.1,113.2,111.8,103.0,99.6,41.9,29.3
Embodiment 8:
2-(2-benzyloxy-4-methoxybenzoyl methyl formyl radical) benzoxazole
In the reaction flask of being furnished with prolong, drying tube, add 2-(2-hydroxyl-4-methoxybenzoyl methyl formyl radical) benzoxazole (and 0.3 the gram, 0.96mmol), K
2CO
3(0.3 gram, 2.54mmol), anhydrous propanone (20ml), catalytic amount KI stirs, the adding bromobenzyl (0.13ml, 1.09mmol), reflux 2.5 hours, filtered while hot concentrates, chloroform and sherwood oil recrystallization get white solid 0.32 gram, yield 85%, mp160-2 ℃.IR (cm
-1):: 3060,2950,1687,1612,1575,755;
1HNMR (δ, ppm, DMSO-d-6): 3.43 (s, 3H, OCH
3), 3.08 (d, J=18,1H, COCHCO), 3.80 (d, J=18,1H, COCHCO), 5.08 (s, 2H, ArCH
2), 6.5 (d, 1H, 3 '-H), 6.815 (dd, 1H, 5 '-H), 6.93 (d, 1H, 5-H), 7.06 (t, 1H, 6-H), 7.20 (t, 1H, 7-H), 7.77 (d, 1H, 4-H), 7.30-7.39 (m, 5H, Ph), 8.02 (d, 1H, 6 '-H); HREIMS (M): observed value 401.126464 C
24H
19NO
5Calculated value 401.126312;
Embodiment 9:
2-(2-acetoxyl group-4-methoxybenzoyl methyl formyl radical) benzoxazole
2-(2-hydroxyl-4-methoxybenzoyl methyl formyl radical) benzoxazole (0.15 gram, 0.54mmol), Ac
2O (2ml) adds in the reaction flask, refluxes 2 hours, and cooling concentrates, and adds suitable quantity of water, uses Na
2CO
3The aqueous solution is transferred pH7-8, filters, and the chloroform recrystallization gets white solid 0.14 gram, yield 81.1%, mp256-8 ℃.IR (cm
-1): 3081,2933,1764,1697,1660,1609,1503;
1HNMR (δ, ppm, DMSO-d6): 2.21 (s, 3H, CH
3), 3.16-3.22 (d, 1H, COCHCO), 3.84-3.93 (d, 1H, COCHCO), 3.4 (s, 3H, OCH
3), 6.11 (s, 1H, 3 '-H), 6.75-6.97 (m, 2H, 5,6-H), 7.03-7.08 (q, 1H, 7-H), 7.17-7.23 (dd, 1H, 5 '-H), 7.33-7.36 (d, 1H, 4-H), 8.31 (d, 1H, 6 '-H); HREIMS (M): observed value 353.089179 C
19H
15NO
6Calculated value 353.089927.
Embodiment 10:
The cytotoxic activity data of embodiment 4～9 compounds.
This mensuration adopts bromination tetrazole indigo plant (MTT) method routinely, promptly use the trysinization tumour cell, to contain the RPMI1640 nutrient solution preparation cell suspension of 10% calf serum, concentration is 10000 cells/ml, and 100 μ l (containing 1000 cells/well) are inoculated in every hole in 96 well culture plates.If different pharmaceutical concentration is established three parallel holes for every group.Put 37 ℃, 5%CO
2Cultivate after 4 days in the incubator and discard nutrient solution, every hole adds 100 μ l 0.5%MTT solution (RPMI 1640 preparations).37 ℃ are incubated 4 hours, abandon supernatant, and every hole adds DMSO 150 μ l dissolving Formazan particle, and vibration detects (reference wavelength 450nm, detection wavelength 570nm) with microplate reader, calculates the inhibiting rate of medicine cell growth.With the drug level logarithmic value inhibiting rate is done linear regression, get straight-line equation, therefrom obtain the half-inhibition concentration (IC of medicine cancer cells
50).Reagent source:
MTT: bromination tetrazole indigo plant (Thiazolyl Blue Tetrazolum Bromide), the import of Sigma company;
RPMI 1640 substratum: GIBCO company product;
Pancreatin (Trypsin): GIBCO company product
DMSO: dimethyl sulfoxide (DMSO), the Beijing Chemical Plant produces;
Calf serum: military region animal doctor's centre of prevention and cure
| Compound | ????????????????IC 50(μg/ml) | |||
| ????KB | ????A2780 | ????Bel＞402 | ||
| General formula (I) compound | R 1=2-benzoxazole, R 2＝H，R 3＝OMe | ????25.92 | ????0.93 | ????＞50 |
| R 1＝R 2=2-benzoxazole, R 3＝H | ????21.25 | ????21.92 | ????＞50 | |
| R 1＝COOH，R 2=2-benzoglyoxaline, R 3＝H | ????43.99 | ????＞50 | ????＞50 | |
| General formula (II) compound | R 1=2-benzoxazole, R 2＝H， R 3＝OMe?????????R 4＝H | ????17.00 | ????32.10 | ????36.01 |
| R 1=2-benzoxazole, R 2＝H， R 3＝OMe?????????R 4＝CH 2Ph | ????50 | ????28.96 | ????29.99 | |
| R 1=2-benzoxazole, R 2＝H R 3＝OMe?????????R 4＝CH 3CO | ????38.53 | ????34.04 | ????＞50 | |
Above-mentioned experimental data shows: The compounds of this invention is that (A2780) and human liver cancer cell 7402 are that (Bel7402) has stronger cytotoxicity to human oral epidermoid carcinoma cell (KB), Proliferation of Human Ovarian Cell 2780.Because the screening of antineoplastic compound is that cytotoxic activity with compound embodies routinely,, can mix the preparation antitumor drug so The compounds of this invention has anti-tumor activity with pharmaceutical carrier.
Claims (10)
1, following general formula (I) compound and open-loop products general formula (II) compound thereof
R wherein
1Expression carboxyl, benzoglyoxaline, benzoxazole, benzothiazole, the benzoglyoxaline of replacement, the benzoxazole of replacement or the benzothiazole of replacement; R
2Expression benzoglyoxaline, benzoxazole, benzothiazole, the benzoglyoxaline of replacement, the benzoxazole of replacement, the benzothiazole or the halogen of replacement; R
3Expression hydroxyl, C
1～10Alkoxyl group, nitro, amino or halogen; R
4Expression H, C
1～10Alkyl, arylalkyl, C
1～10Alkyloyl or aromatic yl silane terephthalamide yl; Its formula of (I) does not comprise R
1=2-benzoglyoxaline, R
2=H, R
3=OCH
3Compound.
2, according to the described general formula of claim 2 (I) compound and open-loop products general formula (II) compound thereof, it is characterized in that: R
1Or R
2The benzoxazole of benzoglyoxaline, the replacement of the replacement of representative, the benzothiazole of replacement are meant on the phenyl ring of benzoglyoxaline, benzoxazole or benzothiazole NO
2Perhaps single substituting group of halogen or disubstituted.
3, according to (I) compound of general formula described in claim 1 and 2 and open-loop products general formula (II) compound thereof, it is characterized in that: halogen can be F, Cl, Br or I.
4. according to (I) compound of general formula described in the claim 1 and open-loop products general formula (II) compound thereof, it is characterized in that: R
4Aryl in aryl, the arylalkyl of representative, the aromatic yl silane terephthalamide yl can be halogen, C
1～10Alkyl, C
1～10Alkoxyl group, the nitro benzene, biphenyl or the naphthalene that replace.
5. according to (I) compound of general formula described in the claim 1 and open-loop products general formula (II) compound thereof, it is characterized in that: R
4Alkyl in the arylalkyl of representative can be C
1～10Alkyl; Alkyloyl in the aromatic yl silane terephthalamide yl can be C
1～10Alkyloyl.
6. according to (I) compound of general formula described in the claim 1 and open-loop products general formula (II) compound thereof, it is characterized in that: R
1Be 2-benzoxazole, carboxyl; R
2Be H, 2-benzoglyoxaline, 2-benzoxazole; R
3Be methoxyl group, H; R
4Be H, benzyl, ethanoyl.
7, the preparation method of general formula (I) compound and open-loop products general formula (II) compound thereof is characterized in that this method may further comprise the steps:
A. the chromone carboxylic acid that following general formula (A) expression replaces is with general formula (A) and the corresponding acyl chlorides of phosphorus pentachloride prepared in reaction in toluene;
General formula (A)
R in the general formula (A)
1Be carboxyl, methoxycarbonyl base or ethoxycarbonyl; R
2Be carboxyl or halogen; R
3Expression C
1～10Alkoxyl group, nitro or halogen;
B. with gained acyl chlorides and O-Phenylene Diamine, Ortho-Aminophenol, o-amino thiophenol, the O-Phenylene Diamine of replacement, the Ortho-Aminophenol of replacement or the o-amino thiophenol prepared in reaction corresponding amide intermediate of replacement;
C. with above-mentioned gained amide intermediate in polyphosphoric acid in 70～160 ℃ of cyclizations, general formula (I) compound; Perhaps with above-mentioned gained amide intermediate in polyphosphoric acid in 140～190 ℃ of cyclizations, R
4Be general formula (II) compound of H, hydrocarbonylation or acidylate get R
4General formula (II) compound for hydrocarbonylation or acidylate; Wherein, amino general formula (I) that replaces and general formula (II) compound obtain corresponding nitro-compound reduction; General formula (I) that hydroxyl replaces and general formula (II) compound are that the compound demethylation that corresponding methoxyl group replaces is obtained.
8, according to the preparation method of described general formula of claim 7 (I) and open-loop products general formula (II) compound thereof, it is characterized in that: the o-amino thiophenol of the O-Phenylene Diamine that replaces described in the b., the Ortho-Aminophenol of replacement or replacement represents on the phenyl ring of O-Phenylene Diamine, Ortho-Aminophenol or o-amino thiophenol NO is arranged
2, single substituting group of F, Cl, Br or I or disubstituted.
9, according to the preparation method of claim 7 or 8 described general formulas (I) and open-loop products general formula (II) compound thereof, it is characterized in that: c. will through a, b step gained acid amides in polyphosphoric acid in 100～140 ℃ of cyclizations, general formula (I) compound; Perhaps with above-mentioned gained acid amides in polyphosphoric acid in 160～180 ℃ of cyclizations, R
4Be general formula (II) compound of H, hydrocarbonylation or acidylate get R
4General formula (II) compound for hydrocarbonylation or acidylate.
10, any one application of compound in the medicine of preparation treatment tumour in the claim 1～6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021128758A CN1155590C (en) | 2002-04-12 | 2002-04-12 | Chromone compounds with antineoplastic activity and its open-loop products and preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021128758A CN1155590C (en) | 2002-04-12 | 2002-04-12 | Chromone compounds with antineoplastic activity and its open-loop products and preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1382688A true CN1382688A (en) | 2002-12-04 |
| CN1155590C CN1155590C (en) | 2004-06-30 |
Family
ID=4742314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021128758A Expired - Fee Related CN1155590C (en) | 2002-04-12 | 2002-04-12 | Chromone compounds with antineoplastic activity and its open-loop products and preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1155590C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013535515A (en) * | 2010-08-18 | 2013-09-12 | サミュメッド リミテッド ライアビリティ カンパニー | Diketones and hydroxyketones as activators of the catenin signaling pathway |
| US9533976B2 (en) | 2013-02-22 | 2017-01-03 | Samumed, Llc | γ-diketones as WNT/β-catenin signaling pathway activators |
| US9795550B2 (en) | 2014-08-20 | 2017-10-24 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| WO2019054386A1 (en) * | 2017-09-12 | 2019-03-21 | 学校法人工学院大学 | Heterocyclic compound or salt thereof, gpr35 agonist, and pharmaceutical composition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2019168170A1 (en) * | 2018-03-02 | 2021-03-04 | 国立大学法人 長崎大学 | Composition for diagnosing chromone derivatives and amyloid-related diseases |
-
2002
- 2002-04-12 CN CNB021128758A patent/CN1155590C/en not_active Expired - Fee Related
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10314832B2 (en) | 2010-08-18 | 2019-06-11 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators |
| JP2017165773A (en) * | 2010-08-18 | 2017-09-21 | サミュメッド リミテッド ライアビリティ カンパニー | Diketones and hydroxyketones as catenin signaling pathway activators |
| US9884053B2 (en) | 2010-08-18 | 2018-02-06 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators |
| US9303010B2 (en) | 2010-08-18 | 2016-04-05 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators |
| US9493437B2 (en) | 2010-08-18 | 2016-11-15 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as Wnt/ β-catenin signaling pathway activators |
| JP2013535515A (en) * | 2010-08-18 | 2013-09-12 | サミュメッド リミテッド ライアビリティ カンパニー | Diketones and hydroxyketones as activators of the catenin signaling pathway |
| JP2017048192A (en) * | 2010-08-18 | 2017-03-09 | サミュメッド リミテッド ライアビリティ カンパニー | Diketones and hydroxyketones as catenin signaling pathway activators |
| US8921413B2 (en) | 2010-08-18 | 2014-12-30 | Samumed, Llc | β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators |
| AU2011291989B2 (en) * | 2010-08-18 | 2015-08-20 | Samumed, Llc | Diketones and hydroxyketones as catenin signaling pathway activators |
| US10457672B2 (en) | 2013-02-22 | 2019-10-29 | Samumed, Llc | γ-diketones as Wnt/β-catenin signaling pathway activators |
| US11673885B2 (en) | 2013-02-22 | 2023-06-13 | Biosplice Therapeutics, Inc. | γ-diketones as Wnt/β-catenin signaling pathway activators |
| US9951053B2 (en) | 2013-02-22 | 2018-04-24 | Samumed, Llc | γ-diketones as Wnt/β-catenin signaling pathway activators |
| US9533976B2 (en) | 2013-02-22 | 2017-01-03 | Samumed, Llc | γ-diketones as WNT/β-catenin signaling pathway activators |
| US11034682B2 (en) | 2013-02-22 | 2021-06-15 | Samumed, Llc | Gamma-diketones as wnt/β-catenin signaling pathway activators |
| US11839679B2 (en) | 2014-08-20 | 2023-12-12 | Biosplice Therapeutics, Inc. | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| US10434052B2 (en) | 2014-08-20 | 2019-10-08 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| US11077046B2 (en) | 2014-08-20 | 2021-08-03 | Biosplice Therapeutics, Inc. | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| US9795550B2 (en) | 2014-08-20 | 2017-10-24 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
| WO2019054386A1 (en) * | 2017-09-12 | 2019-03-21 | 学校法人工学院大学 | Heterocyclic compound or salt thereof, gpr35 agonist, and pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1155590C (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN87101984A (en) | Carbostyril carboxylic acid derivatives and preparation method thereof | |
| CN1450989A (en) | 7-substituted tetracycline compounds | |
| CN1123571C (en) | 1-(3-heteroarylpropyl-or-prop-2-enyl)-4-benzylpiperidines used as NMDA receptor antagonists | |
| CN1708495A (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
| CN87105516A (en) | Phenyl crotonamide compound that replaces and preparation method thereof | |
| CN109053625A (en) | A kind of preparation method replacing benzothiazole C2 alkyl derivative | |
| CN86102449A (en) | The improved method for preparing quinoline-3-carboxylic acid class antiseptic-germicide | |
| CN101717359B (en) | Method for synthesizing indapamide | |
| CN1155590C (en) | Chromone compounds with antineoplastic activity and its open-loop products and preparing process | |
| CN106632033A (en) | Preparation method of lenvatinib | |
| CN1009826B (en) | The method for preparing quinoline compound | |
| CN1019911C (en) | Benzoxazine derivative and processes for preparing same | |
| CN100344615C (en) | Production of N-(pyrrolo[2,3-d] pyrimidine-5-) acyl glusate derivative and intermediate | |
| CN1235882C (en) | Aliphatic amino substituted indole quinoline derivatives, their preparation method and pharmaceutical application | |
| CN1127482C (en) | Sulfuryl diphenyl indole compound and preparation process and use in medicine | |
| CN1282738A (en) | Improved method for sgnthesizing 6,9-bis[(2-aminoethyl) amino] benz[g] isoquinoline-5, 10-diketone and its dimaleate | |
| CN1083066A (en) | Novel thienothiazine derivatives and their preparation method and application | |
| CN1325494C (en) | 3-substituted nalidixic acid analog compound and its preparation method and uses in pharmacy | |
| CN100488960C (en) | 2-substituted quinolone compound and use in pharmacy | |
| CN1793145A (en) | 7-bit substituted comptothecine kind compound and pharmaceutical use thereof | |
| CN1299811A (en) | Alpha-alkylacyl-beta-substituted benzoyl-beta-phenylpropionyl aniline and its synthesis and use | |
| CN1683349A (en) | 2-imino-tetrahydro-1,3-benzothiazine derivative and its preparing method | |
| CN103709146B (en) | One class is containing the quinolin-4-amines derivative of benzimidazole structure, its method for making and medicinal use | |
| CN1304373C (en) | Method for preparing aripiprazole and its intermediate | |
| CN1235880C (en) | Quinolinenone kind derivative and its accetable salt, its preparation method, application in preparation of alipyrazole and preparation of alipyrazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |